[go: up one dir, main page]

EP1181045A4 - USE OF ASPARAGINASE AND GLUTAMINASE TO TREAT AUTOIMMUNE DISEASES OR DISEASES CAUSED BY GRAFT REJECTION - Google Patents

USE OF ASPARAGINASE AND GLUTAMINASE TO TREAT AUTOIMMUNE DISEASES OR DISEASES CAUSED BY GRAFT REJECTION

Info

Publication number
EP1181045A4
EP1181045A4 EP00919649A EP00919649A EP1181045A4 EP 1181045 A4 EP1181045 A4 EP 1181045A4 EP 00919649 A EP00919649 A EP 00919649A EP 00919649 A EP00919649 A EP 00919649A EP 1181045 A4 EP1181045 A4 EP 1181045A4
Authority
EP
European Patent Office
Prior art keywords
glutaminase
asparaginase
diseases
graft rejection
treat autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00919649A
Other languages
German (de)
French (fr)
Other versions
EP1181045A1 (en
Inventor
Donald L Durden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Los Angeles
Original Assignee
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Los Angeles filed Critical Childrens Hospital Los Angeles
Publication of EP1181045A1 publication Critical patent/EP1181045A1/en
Publication of EP1181045A4 publication Critical patent/EP1181045A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01002—Glutaminase (3.5.1.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
EP00919649A 1999-04-02 2000-03-24 USE OF ASPARAGINASE AND GLUTAMINASE TO TREAT AUTOIMMUNE DISEASES OR DISEASES CAUSED BY GRAFT REJECTION Withdrawn EP1181045A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12766299P 1999-04-02 1999-04-02
US127662P 1999-04-02
PCT/US2000/007981 WO2000059533A1 (en) 1999-04-02 2000-03-24 Use of asparaginase and glutaminase to treat autoimmune disease and graft versus host disease

Publications (2)

Publication Number Publication Date
EP1181045A1 EP1181045A1 (en) 2002-02-27
EP1181045A4 true EP1181045A4 (en) 2003-04-23

Family

ID=22431251

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00919649A Withdrawn EP1181045A4 (en) 1999-04-02 2000-03-24 USE OF ASPARAGINASE AND GLUTAMINASE TO TREAT AUTOIMMUNE DISEASES OR DISEASES CAUSED BY GRAFT REJECTION

Country Status (4)

Country Link
EP (1) EP1181045A4 (en)
AU (1) AU4030200A (en)
CA (1) CA2368230A1 (en)
WO (1) WO2000059533A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991183A1 (en) 2014-01-06 2020-02-28 Ризен Фармасьютикалз Са NEW GLUTAMINASE INHIBITORS
EP3535386A4 (en) * 2016-11-04 2020-04-15 Georgia State University Research Foundation, Inc. ENDOTOXIN-FREE ASPARAGINASE
JP6921439B2 (en) * 2016-11-08 2021-08-18 ウニべルシタ デッリ ストゥーディ ディ パビア Highly stable, protease resistant E. coli asparaginase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039732A1 (en) * 1998-02-09 1999-08-12 Aventis Pharmaceuticals Products Inc. Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217566T3 (en) * 1997-06-09 2004-11-01 Childrens Hospital Of Los Angeles USE OF WOLINELLA SUCCIONOGENES ASPARAGINASE TO TREAT DISEASES ASSOCIATED WITH THE ASPARAGINE DEPENDENCY.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039732A1 (en) * 1998-02-09 1999-08-12 Aventis Pharmaceuticals Products Inc. Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABUCHOWSKI A ET AL: "CANCER THERAPY WITH CHEMICALLY MODIFIED ENZYMES. I. ANTITUMOR PROPERTIES OF POLYETHYLENE GLYCOL-ASPARAGINASE CONJUGATES", CANCER BIOCHEMISTRY BIOPHYSICS, GORDON AND BREACH SCIENCE PUBLISHER, INC, US, vol. 7, 1984, pages 175 - 186, XP000199119, ISSN: 0305-7232 *
DURDEN D L ET AL: "Comparison of the Immunosupressive Effects of Asparaginases from Escherichia coli and Vibrio succinogenes", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 40, no. 4, 1 April 1980 (1980-04-01), pages 1125 - 1129, XP002082325, ISSN: 0008-5472 *
ROBERTS J ET AL: "INHIBITION OF MOUSE RETROVIRAL DISEASE BY BIOACTIVE GLUTAMINASE ASPARAGINASE", JOURNAL OF GENERAL VIROLOGY, vol. 72, no. 2, 1991, pages 299 - 306, XP009006472, ISSN: 0022-1317 *
See also references of WO0059533A1 *
VERONESE F M ET AL: "Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol)", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 40, no. 3, 1 July 1996 (1996-07-01), pages 199 - 209, XP004037365, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
WO2000059533A9 (en) 2002-07-18
AU4030200A (en) 2000-10-23
EP1181045A1 (en) 2002-02-27
WO2000059533A1 (en) 2000-10-12
CA2368230A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
EP1098902A4 (en) TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
FR2732357B1 (en) VIRAL VECTORS AND USE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS, ESPECIALLY RESTENOSIS
EP1007089A4 (en) COAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS
ATE293417T1 (en) SCLEROTIC PROSTHESIS FOR THE TREATMENT OF PRESBIOUS SIGHT AND OTHER EYE DISEASES
FR05C0033I2 (en) R-ENANTIOMER OF N-PROPARGYL-1-AMINO-INDANE FOR THE TREATMENT OF VARIOUS DISEASES AND ITS MESYLATE, ESYLATE AND SULFATE
IS5405A (en) Prostaglandin agonists and their use in the treatment of bone disorders
EP0925046A4 (en) TOPICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF HEMORROIDAL PAIN
FR2754713B1 (en) USE OF COMPLEXES FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF SENSITIVE SKIN, PREPARATION METHOD AND HYPOALLERGENIC COMPOSITIONS
DE69830728D1 (en) MEDICAMENT FOR THE TREATMENT OF COMMON WATER AND HARN INCONTINENCE
ATE319453T1 (en) REBOXETINE FOR THE TREATMENT OF FIBROMYALGIA AND OTHER SOMATOFORM DISORDERS
EP0866710A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE DEFICITS
FR2739003B1 (en) FOAM POUCH FOR TOPICAL SKIN CARE AND TREATMENT
FI963083L (en) Treatment of normotensive glaucoma with angiotensin II antagonists
BR9708270A (en) Titanium or titanium alloy and method of surface treatment thereof
MA24332A1 (en) USE OF 1-HYDROXY-2- PYRIDONES FOR THE TREATMENT OF SKIN INFECTIONS
DE69620691D1 (en) Therapeutic agent for the treatment of hypercholesterolemia
EP1102788A4 (en) PREVENTION AND TREATMENT OF VIRAL DISEASES
DE69841550D1 (en) TREATMENT OF FIBROMYALGIA AND RELATED DISEASES
DE69807466D1 (en) TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES
PT898566E (en) SUBSTITUTED BENZYLAMINES AND THEIR USE IN TREATMENT OF DEPRESSION
EP1015034A4 (en) CONSTRUCTION AND USE OF GENES ENCODING PATHOGENIC EPITOPES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DE69825319D1 (en) PREPARATION FOR THE PREVENTION AND TREATMENT OF INFLAMMATION
FR2717080B1 (en) Use of eipriprodil and its enantiomers for the preparation of medicaments useful in the treatment of peripheral neuropathies and central neurodegenerative diseases.
EP1469852A4 (en) DONORS OF NITROGEN MONOXIDE FOR THE TREATMENT OF DISEASES AND INJURIES
DE69829217D1 (en) DEVICE FOR THE THERAPEUTIC TREATMENT OF BLOOD VESSELS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030310

17Q First examination report despatched

Effective date: 20030620

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031231